GT200300150A - Inhibidores de quinasas - Google Patents
Inhibidores de quinasasInfo
- Publication number
- GT200300150A GT200300150A GT200300150A GT200300150A GT200300150A GT 200300150 A GT200300150 A GT 200300150A GT 200300150 A GT200300150 A GT 200300150A GT 200300150 A GT200300150 A GT 200300150A GT 200300150 A GT200300150 A GT 200300150A
- Authority
- GT
- Guatemala
- Prior art keywords
- kinase inhibitors
- thyrosinaquinase
- retinopostics
- dysteros
- quinasa
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE AL COMPUESTO QUE APARECE EN EL RESUMEN EN EL QUE C,D,B,A,R1,R2,R3,R4,R5,R6, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS INHIBEN LAS ENZIMAS QUINASA Y TIROSINAQUINASA DEPENDIENTES DE LA CICLINA POR LO QUE SON DE UTILIDAD PRINCIPALMENTE EN TRASTORNOS DE PROLIFERACION CELULAR TALES COMO ANGIOGENESIS, CANCER, ADEMAS DE OTRAS PATOLOGIAS COMO RETINOPATIA DIABETICA, ATEROSCLEROSIS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39863802P | 2002-07-25 | 2002-07-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT200300150A true GT200300150A (es) | 2004-06-08 |
Family
ID=31188438
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT200300150A GT200300150A (es) | 2002-07-25 | 2003-07-23 | Inhibidores de quinasas |
Country Status (18)
Country | Link |
---|---|
US (1) | US7196090B2 (es) |
EP (1) | EP1549651B1 (es) |
JP (1) | JP2005538992A (es) |
AR (1) | AR040513A1 (es) |
AT (1) | ATE452891T1 (es) |
AU (1) | AU2003249442A1 (es) |
BR (1) | BR0312867A (es) |
CA (1) | CA2493633C (es) |
DE (1) | DE60330694D1 (es) |
ES (1) | ES2335659T3 (es) |
GT (1) | GT200300150A (es) |
HN (1) | HN2003000227A (es) |
MX (1) | MXPA05000814A (es) |
PA (1) | PA8577501A1 (es) |
PE (1) | PE20040688A1 (es) |
TW (1) | TW200413375A (es) |
UY (1) | UY27906A1 (es) |
WO (1) | WO2004011465A1 (es) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8236048B2 (en) * | 2000-05-12 | 2012-08-07 | Cordis Corporation | Drug/drug delivery systems for the prevention and treatment of vascular disease |
JP4214729B2 (ja) * | 2002-07-25 | 2009-01-28 | コニカミノルタホールディングス株式会社 | 硬化性白インク組成物 |
US7084270B2 (en) | 2002-08-14 | 2006-08-01 | Hoffman-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
US7129351B2 (en) * | 2002-11-04 | 2006-10-31 | Hoffmann-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
CN100497339C (zh) * | 2003-04-10 | 2009-06-10 | 霍夫曼-拉罗奇有限公司 | 嘧啶并化合物 |
GB0313511D0 (en) * | 2003-06-11 | 2003-07-16 | Cyclacel Ltd | Combination |
EP1651648A4 (en) * | 2003-07-29 | 2009-09-02 | Irm Llc | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS |
TW200526224A (en) * | 2003-12-22 | 2005-08-16 | Alcon Inc | Short form c-Maf transcription factor antagonists for treatment of glaucoma |
US7494993B2 (en) | 2004-08-31 | 2009-02-24 | Hoffmann-La Roche Inc. | Amide derivatives of 7-amino-3-phenyl-dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents |
US7655651B2 (en) | 2004-08-31 | 2010-02-02 | Hoffmann-La Roche Inc. | Amide derivatives of 3-phenyl-dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents |
WO2006038112A1 (en) * | 2004-10-01 | 2006-04-13 | Warner-Lambert Company Llc | Use of kinase inhibitors to promote neochondrogenesis |
FR2876584B1 (fr) * | 2004-10-15 | 2007-04-13 | Centre Nat Rech Scient Cnrse | Utilisation de la kenpaullone pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules |
EP1868663B1 (en) * | 2005-03-23 | 2011-11-16 | Abbott Laboratories | Delivery of highly lipophilic agents via medical devices |
EP1931667A1 (en) * | 2005-09-28 | 2008-06-18 | Ranbaxy Laboratories Limited | Pyrido-pyridimidine derivatives useful as antiinflammatory agents |
DK1954697T3 (da) * | 2005-10-21 | 2010-06-14 | Glaxo Group Ltd | Peri-kondenserede tricykliske forbindelser, der er anvendelige som antibakterielle midler |
JP2009514627A (ja) * | 2005-11-10 | 2009-04-09 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 再狭窄の低減 |
SG152296A1 (en) * | 2005-11-21 | 2009-05-29 | Anadys Pharmaceuticals Inc | Novel process for the preparation of 5-amino-3h-thiazolo[4,5-d]pyrimidin-2- one |
DE602006013878D1 (de) | 2005-12-22 | 2010-06-02 | Glaxo Group Ltd | Heterocyclische verbindungen, ihre herstellung und ihre verwendung als antibakterielle mittel |
JP2009525292A (ja) | 2006-01-31 | 2009-07-09 | エフ.ホフマン−ラ ロシュ アーゲー | 7h−ピリド[3,4−d]ピリミジン−8−オン、それらの製造及びプロテインキナーゼ阻害剤としての使用 |
US7897762B2 (en) * | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
JP2010505881A (ja) * | 2006-10-05 | 2010-02-25 | ギリアード・パロ・アルト・インコーポレイテッド | ステアロイルCoAデサチュラーゼインヒビターとして使用するための二環式窒素含有複素環式化合物 |
US7893066B2 (en) | 2006-10-05 | 2011-02-22 | Gilead Palo Alto, Inc. | Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors |
WO2008055842A1 (en) * | 2006-11-09 | 2008-05-15 | F. Hoffmann-La Roche Ag | Substituted 6-phenyl-pyrido [2,3-d] pyrimidin-7-one derivatives as kinase inhibitors and methods for using the same |
WO2008078100A2 (en) | 2006-12-22 | 2008-07-03 | Astex Therapeutics Limited | Tricyclic amine derivatives as protein tyrosine kinase inhibitors |
CN101679408B (zh) * | 2006-12-22 | 2016-04-27 | Astex治疗学有限公司 | 作为fgfr抑制剂的双环杂环化合物 |
US8131527B1 (en) | 2006-12-22 | 2012-03-06 | Astex Therapeutics Ltd. | FGFR pharmacophore compounds |
US7662819B2 (en) | 2007-04-09 | 2010-02-16 | Gilead Palo Alto, Inc. | Pteridinone derivatives for use as stearoyl CoA desaturase inhibitors |
WO2008147687A1 (en) * | 2007-05-21 | 2008-12-04 | Mayo Foundation For Medical Education And Research | Treating pancreatitis |
CN101784551A (zh) | 2007-06-15 | 2010-07-21 | 万有制药株式会社 | 二环苯胺衍生物 |
WO2009016486A2 (en) * | 2007-08-02 | 2009-02-05 | Compugen, Ltd | Use of nmda receptor antagonists for treatment of urologic tumors |
GB0720038D0 (en) * | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
GB0720041D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New Compounds |
ATE551342T1 (de) * | 2008-02-22 | 2012-04-15 | Irm Llc | Heterocyclische verbindungen und zusammensetzungen als c-kit- und pdgfr- kinasehemmer |
JP2011516546A (ja) * | 2008-04-10 | 2011-05-26 | ギリアード サイエンシーズ, インコーポレイテッド | ステアロイル−CoAデサチュラーゼのインヒビターとして使用するための二環式窒素含有複素環化合物 |
GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
US20100267752A1 (en) * | 2008-10-15 | 2010-10-21 | Gilead Palo Alto, Inc. | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS |
CA2745959A1 (en) | 2008-12-12 | 2010-06-17 | Msd K.K. | Dihydropyrimidopyrimidine derivatives |
CA2745970A1 (en) | 2008-12-12 | 2010-06-17 | Msd K.K. | Dihydropyrimidopyrimidine derivative |
GB0906470D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
US8663210B2 (en) | 2009-05-13 | 2014-03-04 | Novian Health, Inc. | Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy |
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
EP2827869A4 (en) | 2012-03-23 | 2015-09-23 | Dennis Brown | COMPOSITIONS AND METHODS FOR IMPROVING THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ITS ANALOGUES INCLUDING MESOINDIGO |
PT3495367T (pt) | 2012-06-13 | 2020-11-12 | Incyte Holdings Corp | Compostos tricíclicos substituídos como inibidores de fgfr |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
AU2014228746B2 (en) | 2013-03-15 | 2018-08-30 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
NZ711376A (en) * | 2013-03-15 | 2020-01-31 | Sanofi Sa | Heteroaryl compounds and uses thereof |
TWI647220B (zh) | 2013-03-15 | 2019-01-11 | 美商西建卡爾有限責任公司 | 雜芳基化合物及其用途 |
TWI715901B (zh) | 2013-04-19 | 2021-01-11 | 美商英塞特控股公司 | 作為fgfr抑制劑之雙環雜環 |
EP3848034A1 (en) | 2014-03-26 | 2021-07-14 | Astex Therapeutics Limited | Cmet-inhibitors for use in delaying the emergence in resistance to fgfr inhibitors |
JP6631616B2 (ja) | 2014-07-26 | 2020-01-15 | ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド | CDK阻害剤としての2−アミノ−ピリド[2,3−d]ピリミジン−7(8H)−オン誘導体及びその使用 |
WO2016055907A1 (en) | 2014-10-10 | 2016-04-14 | Pfizer Inc. | Synergistic auristatin combinations |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
CN104478742A (zh) * | 2014-11-24 | 2015-04-01 | 苏州乔纳森新材料科技有限公司 | 一种氟代化合物及其制备方法 |
JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
CN113004278B (zh) | 2015-02-20 | 2023-07-21 | 因赛特控股公司 | 作为fgfr抑制剂的双环杂环 |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
HUE055978T2 (hu) * | 2016-08-15 | 2022-01-28 | Pfizer | Piridopirimidinon CDK2/4/6 inhibitorok |
GB201703881D0 (en) | 2017-03-10 | 2017-04-26 | Almac Discovery Ltd | Pharmaceutical compounds |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
CN109836427B (zh) * | 2017-11-29 | 2022-04-15 | 暨南大学 | 嘧啶并嘧啶酮类化合物及其应用 |
WO2019213544A2 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
CR20200591A (es) | 2018-05-04 | 2021-03-31 | Incyte Corp | Sales de un inhibidor de fgfr |
PE20212303A1 (es) * | 2018-12-27 | 2021-12-10 | Les Laboratoires Servier Sas | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer |
WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
TW202128685A (zh) | 2019-10-14 | 2021-08-01 | 美商英塞特公司 | 作為fgfr抑制劑之雙環雜環 |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
CA3162010A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2949466A (en) | 1958-03-04 | 1960-08-16 | Parke Davis & Co | Pyrimidine compounds and means of producing the same |
US3912723A (en) | 1971-03-29 | 1975-10-14 | Pfizer | 2-Phenyl-as-triazine-3,5(2H,4H)diones |
US4425346A (en) | 1980-08-01 | 1984-01-10 | Smith And Nephew Associated Companies Limited | Pharmaceutical compositions |
JPS60226882A (ja) | 1984-04-24 | 1985-11-12 | Nippon Zoki Pharmaceut Co Ltd | 新規ピリミドピリミジン誘導体 |
US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
WO1996013262A1 (en) | 1994-10-27 | 1996-05-09 | Merck & Co., Inc. | Muscarine antagonists |
ES2146782T3 (es) | 1994-11-14 | 2000-08-16 | Warner Lambert Co | 6-aril-pirido(2,3-d)pirimidinas y naftiridinas para la inhibicion de la proliferacion celular inducida por la proteina tirosina quinasa. |
IL117923A (en) | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
RO121900B1 (ro) | 1996-04-12 | 2008-07-30 | Warner-Lambert Company | Compuşi inhibitori, ireversibili, ai tirozin kinazelor, compoziţie farmaceutică care îi conţine şi utilizarea acestora |
NZ502704A (en) * | 1997-08-20 | 2002-06-28 | Warner Lambert Co | Naphthyridinones and pharmaceuticals thereof and their use in inhibiting cellular proliferation and protein tyrosine kinase or cell cycle kinase enzymatic activity |
AU763839B2 (en) | 1998-05-26 | 2003-07-31 | Warner-Lambert Company | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation |
CN1150195C (zh) | 1998-10-23 | 2004-05-19 | 霍夫曼-拉罗奇有限公司 | 双环氮杂环 |
HUP0202713A3 (en) * | 1999-09-15 | 2005-02-28 | Warner Lambert Co | Pteridinones as kinase inhibitors |
BR0014973A (pt) | 1999-10-21 | 2002-07-16 | Hoffmann La Roche Ag G | Heterociclos de nitrogênio bicìclico de alquilamino substituìdo como inibidores de proteìna quinase p38 |
CZ20021744A3 (cs) | 1999-10-21 | 2002-08-14 | F. Hoffmann-La Roche Ag | Bicyklické dusíkové heterocykly substituované heteroalkylaminoskupinou jako inhibitory P38 proteinkinázy |
MY141144A (en) | 2000-03-02 | 2010-03-15 | Smithkline Beecham Corp | 1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
MXPA03000289A (es) * | 2000-08-04 | 2003-06-06 | Warner Lambert Co | Proceso para preparar 2-(4-piridil) amino-6-dialquiloxifenil-pirido (2,3-d) pirimidin-7-onas.. |
BR0112857A (pt) * | 2000-08-04 | 2005-02-09 | Warner Lambert Co | Compostos 2-(4-piridil)amino-6-dialcoxifenil-pirido-[2,3-d]pirimidin- 7-onas |
BR0113037A (pt) * | 2000-08-04 | 2004-01-20 | Warner Lambert Co | Processo para preparação de 2-(4-piridil) amino-6-dialquilox fenil-pirido[2,3-d] pirimidin-7-onas |
-
2003
- 2003-07-17 US US10/621,983 patent/US7196090B2/en not_active Expired - Fee Related
- 2003-07-17 PA PA20038577501A patent/PA8577501A1/es unknown
- 2003-07-21 ES ES03771234T patent/ES2335659T3/es not_active Expired - Lifetime
- 2003-07-21 CA CA002493633A patent/CA2493633C/en not_active Expired - Fee Related
- 2003-07-21 PE PE2003000722A patent/PE20040688A1/es not_active Application Discontinuation
- 2003-07-21 WO PCT/IB2003/003359 patent/WO2004011465A1/en active Application Filing
- 2003-07-21 JP JP2004524024A patent/JP2005538992A/ja active Pending
- 2003-07-21 AU AU2003249442A patent/AU2003249442A1/en not_active Abandoned
- 2003-07-21 EP EP03771234A patent/EP1549651B1/en not_active Expired - Lifetime
- 2003-07-21 MX MXPA05000814A patent/MXPA05000814A/es unknown
- 2003-07-21 BR BR0312867-9A patent/BR0312867A/pt not_active IP Right Cessation
- 2003-07-21 DE DE60330694T patent/DE60330694D1/de not_active Expired - Lifetime
- 2003-07-21 AT AT03771234T patent/ATE452891T1/de not_active IP Right Cessation
- 2003-07-23 GT GT200300150A patent/GT200300150A/es unknown
- 2003-07-23 AR AR20030102643A patent/AR040513A1/es unknown
- 2003-07-24 HN HN2003000227A patent/HN2003000227A/es unknown
- 2003-07-24 UY UY27906A patent/UY27906A1/es not_active Application Discontinuation
- 2003-07-24 TW TW092120237A patent/TW200413375A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
BR0312867A (pt) | 2005-06-14 |
EP1549651A1 (en) | 2005-07-06 |
AU2003249442A1 (en) | 2004-02-16 |
PE20040688A1 (es) | 2004-10-06 |
ATE452891T1 (de) | 2010-01-15 |
ES2335659T3 (es) | 2010-03-31 |
US20040019210A1 (en) | 2004-01-29 |
EP1549651B1 (en) | 2009-12-23 |
AR040513A1 (es) | 2005-04-06 |
JP2005538992A (ja) | 2005-12-22 |
HN2003000227A (es) | 2005-10-20 |
MXPA05000814A (es) | 2005-04-19 |
CA2493633C (en) | 2009-04-07 |
UY27906A1 (es) | 2004-02-27 |
CA2493633A1 (en) | 2004-02-05 |
DE60330694D1 (de) | 2010-02-04 |
US7196090B2 (en) | 2007-03-27 |
WO2004011465A1 (en) | 2004-02-05 |
TW200413375A (en) | 2004-08-01 |
PA8577501A1 (es) | 2004-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT200300150A (es) | Inhibidores de quinasas | |
GT200300087A (es) | 2-(2,6-diclorofenil)-diarilimidazoles | |
GT200300093A (es) | Inhibidores de metaloproteinasa de heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida | |
GT200300005A (es) | 2-(piridin-2-ilamino)-pirido[2,3-d] pirimidin-7-onas | |
GT200400032A (es) | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transformante (tgf) | |
GT200300098A (es) | Inhibidores de metaloproteinasa de aril-heteroariloxi-ariloxi-pirimidina-2,4,6-triona | |
GT200400161A (es) | Piridinonas sustituidas | |
UY3402Q (es) | Diseno de tractor | |
GT200500226A (es) | Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa | |
GT200600181A (es) | Derivados de amida sustituida y metodos de uso | |
GT200500008A (es) | Intermediarios de quinolina como inhibidores de receptores de tirosina quinasas y la sintesis de los mismos | |
GT200300097A (es) | Inhibidores de metaloproteinasa de triaril-oxi-aril-espiro-pirimidina-2,4,6-triona | |
GT200500103A (es) | 4-fenilamino-quinazolin-6-il-amidas | |
GT200200122A (es) | Imidazotriazinas | |
BRPI0411897A (pt) | pirroldihidroisoquinolinas como inibidores de pde10 | |
GT200500101A (es) | Compuestos de metil-aril o heteroaril-amida sustituida | |
GEP20094785B (en) | Pyrrolopyrazoles, potent kinase inhibitors | |
GT200300101A (es) | Pirazolopiridinas substituidas con carbamato | |
GT200500272A (es) | 2-anilinopirimidinas sustituidas como inhibidores de la quinasa del ciclo celular o del receptor de la tirosina quinasa, su preparacion y su uso como medicamentos | |
SE0301372D0 (sv) | Novel compounds | |
GT200300296A (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
GT200400013A (es) | Compuestos de pirazolotriazina y usos de los mismos | |
EA200500017A1 (ru) | Новые соединения | |
SE0101675D0 (sv) | Novel composition | |
GT200400050A (es) | Compuestos de quinolina y quinoxalina |